Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31681271 | 0.86 | LMNA (0.43) | LMNATDP1MEN1MAPTTHRB | |
| SCHEMBL7750100 | 0.85 | LMNA (0.47) | LMNATDP1MEN1MAPTTHRB | |
| SCHEMBL135011 | 0.84 | LMNA (0.41) | LMNATDP1MEN1MAPTTHRB | |
| SCHEMBL41357 | 0.84 | LMNA (0.63) | LMNATDP1MEN1MAPTTHRB | |
| SCHEMBL22027491 | 0.84 | LMNA (0.43) | LMNATDP1MEN1MAPTTHRB | |
| SCHEMBL4725918 | 0.84 | LMNA (0.43) | LMNATDP1MEN1MAPTTHRB | |
| SCHEMBL559842 | 0.83 | LMNA (0.40) | LMNATDP1MEN1MAPTTHRB | |
| Potassium SCHEMBL30593807 | 0.83 | LMNA (0.42) | LMNATDP1MEN1MAPTTHRB | |
| SCHEMBL634270 | 0.83 | MAPT (0.42) | LMNATDP1MEN1MAPTTHRB | |
| Bromide SCHEMBL4727423 | 0.83 | LMNA (0.42) | LMNATDP1MEN1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466836-B2 | Spiropyran hydrogels and light-driven expansion thereof | NORTHWESTERN UNIVERSITY (US) | 2025-11-11 | — | — | US | disclosed |
| US-20220298169-A1 | SPIROPYRAN HYDROGELS AND LIGHT-DRIVEN EXPANSION THEREOF | UNITED STATES DEPARTMENT OF ENERGY | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466836-B2 | Spiropyran hydrogels and light-driven expansion thereof | CRY1, PASK, VCL | LMNA 2052/4885TDP1 3506/4885MEN1 3960/4885 |
| US-20220298169-A1 | SPIROPYRAN HYDROGELS AND LIGHT-DRIVEN EXPANSION THEREOF | CRY1, PASK, VCL | LMNA 2052/4885TDP1 3506/4885MEN1 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.